Table: Nxera Pharma -9-MTH group results (IFRS)

Nxera Pharma

30/10/2026 06:30

30 Oct 2026 06:30:20

 Oct 30 (Reuters)-
Nxera Pharma
 CONSOLIDATED FINANCIAL HIGHLIGHTS

 (in billions of yen unless specified)

               9 months ended  9 months ended    Year to
              Sep 30, 2026    Sep 30, 2025   Dec 31, 2026
                 LATEST         YEAR-AGO        LATEST
                RESULTS         RESULTS        FORECAST
Sales            27.74           21.85            --
              (+27.0 pct)      (-0.6 pct)
Operating         3.18         loss 5.91          --
Pretax            2.57         loss 6.84          --
Net               2.33         loss 4.81          --
EPS Basic      25.61 yen     loss 53.31 yen       --
EPS Diluted    23.17 yen     loss 53.31 yen       --
Ann Div            --           0.00 yen       0.00 yen
-Q2 div         0.00 yen        0.00 yen          --
-Q4 div            --           0.00 yen       0.00 yen


 NOTE - Nxera Pharma.
(Figures are reported based on international accounting rules (IFRS).)

If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
 2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
 To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T